ST. LOUIS--()--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it has acquired drug development consultancy firm Great Lakes Drug Development, Inc. ("GLDD"), based in Brighton, MI. Both companies possess considerable expertise in pharmacokinetic (PK) and pharmacodynamic (PD) analysis, project management, and pharmacometric modeling and simulation. GLDD focuses on early development work, while Certara's products and services span the entire drug development continuum. Financial details about the transaction have not been disclosed.
"This acquisition will enable us to leverage the significant synergies between Certara's and GLDD's business focus, experience, and culture, while expanding our customer base"
"This acquisition will enable us to leverage the significant synergies between Certara's and GLDD's business focus, experience, and culture, while expanding our customer base," said Daniel Weiner, Ph.D., senior vice president and general manager at Certara.
The addition of GLDD builds on the capabilities Tripos®, Pharsight® and Simcyp™ bring to Certara.
GLDD's Chief Executive Officer, David Hermann, said, "This is an exciting stage in our company's evolution. We look forward to joining Certara's Pharsight Consulting Services to enhance their capabilities and provide our customers with access to additional services and expertise."
The GLDD office in Brighton, MI will become the sixth in Certara's worldwide consultancy operations including 75 Ph.D. staff in Sunnyvale, CA; Cary, NC; Montreal, Canada; Tokyo, Japan; and Sheffield, England.
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.
About Great Lakes Drug Development, Inc.
Great Lakes Drug Development provides strategic, operational and interim management support for early drug development projects. The company's services include clinical pharmacology development support; pharmacokinetic, pharmacodynamic and biostatistical analysis and reporting; program / project management; and pharmacometric modeling and simulation techniques to guide early and informed decision making.